Metoclopramide Accord (Metoclopramide Hydrochloride)

Metoclopramide blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone and the gastrointestinal tract, reducing the vomiting reflex. It also antagonizes 5‑HT3 receptors and stimulates acetylcholine release, which together accelerate gastric emptying and improve gastrointestinal motility.

The appropriate dose of Metoclopramide Accord is determined by the prescribing healthcare professional based on the patient’s age, condition, and response to therapy. Dosage regimens are individualized and should follow the prescriber’s instructions and local labeling.

Metoclopramide is classified as pregnancy category B, indicating no evidence of risk in animal studies but a lack of well‑controlled human data. It may be used during pregnancy only if the potential benefit justifies the potential risk. Caution is advised during breastfeeding, and a clinician should assess safety.

To request Metoclopramide Accord, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoclopramide differs from many antiemetics by combining dopamine antagonism with pro‑kinetic activity, making it effective for both nausea control and gastric motility. Other agents, such as ondansetron, act primarily on serotonin receptors and lack pro‑kinetic effects, so the choice depends on the clinical scenario.

Metoclopramide Accord should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency.

Metoclopramide Accord is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact timing and frequency depend on the indication and the individual patient’s treatment plan.

Serious risks include extrapyramidal reactions such as dystonia, tardive dyskinesia, and the rare but life‑threatening neuroleptic malignant syndrome. Patients should be monitored for any involuntary movements, muscle rigidity, fever, or changes in mental status, and the drug should be discontinued if such symptoms appear.

Metoclopramide Accord is contraindicated in individuals with known hypersensitivity to metoclopramide or any component of the formulation, and in patients with a history of seizure disorders, pheochromocytoma, or severe gastrointestinal obstruction. Caution is also advised for those with Parkinson’s disease or other movement disorders.